DOCSLIB.ORG

BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available BMJ Open: first published as 10.1136/bmjopen-2019-029467 on 26 July 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 23, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2019-029467 on 26 July 2019. Downloaded from Pharmacological interventions for the prevention of foetal growth restriction: protocol for a systematic review and network meta-analysis. ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2019-029467 Article Type: Protocol Date Submitted by the 28-Jan-2019 Author: Complete List of Authors: Bettiol, Alessandra; Universita degli Studi di Firenze Dipartimento di Neuroscienze Psicologia Area del Farmaco e Salute del Bambino Lombardi, Niccolò; Universita degli Studi di Firenze Dipartimento di Neuroscienze Psicologia Area del Farmaco e Salute del Bambino Crescioli, Giada; Universita degli Studi di Firenze Dipartimento di Neuroscienze Psicologia Area del Farmaco e Salute del Bambino Ravaldi, Claudia; Universita degli Studi di Firenze, Department of Health Sciences,; Charity for Healthy Pregnancy, Stillbirth and Perinatal Loss Support Vannacci, Alfredo; Florence University, Department of Pharmacology Fetal medicine < OBSTETRICS, Maternal medicine < OBSTETRICS, http://bmjopen.bmj.com/ Keywords: PREVENTIVE MEDICINE, CLINICAL PHARMACOLOGY, PERINATOLOGY on September 23, 2021 by guest. Protected copyright. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 18 BMJ Open 1 2 3 Pharmacological interventions for the prevention of foetal growth restriction: protocol for a 4 BMJ Open: first published as 10.1136/bmjopen-2019-029467 on 26 July 2019. Downloaded from 5 systematic review and network meta-analysis. 6 7 8 9 Alessandra Bettiol1, Niccolò Lombardi1, Giada Crescioli1, Claudia Ravaldi2,3, Alfredo Vannacci1,2 10 11 12 13 14 1. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and 15 16 Toxicology, University of Florence; Tuscan Regional Centre of Pharmacovigilance and Phytovigilance, 17 18 Florence, Italy For peer review only 19 20 2. CiaoLapo, Charity for Healthy Pregnancy, Stillbirth and Perinatal Loss Support, Prato, Italy 21 22 3. Department of Health Sciences, University of Florence, Florence, Italy 23 24 25 26 Email: Alessandra Bettiol [email protected]; Niccolò Lombardi [email protected]; Giada 27 28 Crescioli [email protected]; Claudia Ravaldi [email protected]; Alfredo Vannacci 29 30 31 [email protected] 32 33 34 35 Corresponding author 36 http://bmjopen.bmj.com/ 37 Prof. Alfredo Vannacci 38 39 Department of Neurosciences, Psychology, Drug Research and Child Health 40 41 University of Florence 42 43 Viale G. Pieraccini, 6 - 50139 - Florence, Italy 44 on September 23, 2021 by guest. Protected copyright. 45 Phone number: +39 055 27 58 206 46 47 Email address: [email protected] 48 49 50 51 52 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open Page 2 of 18 1 2 3 ABSTRACT 4 BMJ Open: first published as 10.1136/bmjopen-2019-029467 on 26 July 2019. Downloaded from 5 Introduction: Foetal growth restriction (FGR) includes different conditions in which a foetus fails to reach 6 7 the full growth, and accounts for 28-45% of non-anomalous stillbirths. The management of FGR is based on 8 9 the prolongation of pregnancy long enough for foetal organs to mature. As for pharmacological management, 10 11 12 most guidelines recommend treatment with low-dose aspirin, while use of heparin is controversial and 13 14 innovative promising therapies are under investigation. As no firm evidence exists to guide clinicians 15 16 towards the most effective therapeutic intervention, this protocol describes methods for a systematic review 17 18 and network meta-analysisFor of pharmacological peer treatmentsreview for FGR onlyprevention. 19 20 Methods and analysis: We will search MEDLINE and Embase for clinical trials and observational studies 21 22 performed on singleton-gestating women with clinically-diagnosed risk of FGR and/or preeclampsia. 23 24 Experimental interventions will include heparin and low-molecular-weight heparin, acetylsalicylic acid, 25 26 antiplatelet agents, phosphodiesterase type 5 inhibitors, maternal VEGF gene therapy, nanoparticles, 27 28 microRNA, statins, nitric oxide donors, hydrogen sulphite, proton pump inhibitors, melatonin, creatine and 29 30 31 N-acetylcysteine, compared between each other or to placebo or no treatment. Primary efficacy outcome is 32 33 FGR. Secondary efficacy outcomes will be preeclampsia, placental abruption, and foetal or neonatal death. 34 35 For the safety outcome, all adverse events reported in included studies and experienced by either mothers or 36 http://bmjopen.bmj.com/ 37 newborns will be considered. 38 39 Two review authors will independently screen title, abstract and full paper text, and will independently 40 41 extract data from included studies. Where possible and appropriate, for primary and secondary efficacy 42 43 outcomes, a network meta-analysis will be performed using a random-effects model within a frequentist 44 on September 23, 2021 by guest. Protected copyright. 45 framework. Adverse events will be narratively described. 46 47 Ethics and dissemination: Results will be disseminated through a peer-reviewed scientific journal, and by 48 49 scientific congresses and meetings. 50 51 52 PROSPERO registration number: CRD42019122831 53 54 55 56 STRENGTHS AND LIMITATIONS OF THIS STUDY 57 58 Both clinical trials and observational studies will be included. 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 3 of 18 BMJ Open 1 2 3 Where possible, results will be synthetized using a network meta-analysis, thus allowing to 4 BMJ Open: first published as 10.1136/bmjopen-2019-029467 on 26 July 2019. Downloaded from 5 simultaneously combine both direct and indirect evidence. 6 7 The study team includes clinicians, pharmacologists, and experts in the field of pregnancy 8 9 10 complications and related therapeutic interventions. 11 12 13 14 Word count: 2508 15 16 17 18 For peer review only 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 http://bmjopen.bmj.com/ 37 38 39 40 41 42 43 44 on September 23, 2021 by guest. Protected copyright. 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open Page 4 of 18 1 2 3 INTRODUCTION 4 BMJ Open: first published as 10.1136/bmjopen-2019-029467 on 26 July 2019. Downloaded from 5 Foetal growth restriction (FGR), also known as intrauterine growth restriction (IUGR), includes different 6 7 conditions in which a foetus fails to reach the full growth. The most common parameter used to measure 8 9 FGR is small for gestational age (SGA) [1] , and is usually defined as an infant with a birthweight for 10 11 12 gestational age <10th centile for a population or customized standard [1]. 13 14 Suboptimal foetal growth is important as SGA babies comprise 28-45% of non-anomalous stillbirths [2,3]. 15 16 Causes of FGR and SGA can be foetus- or mother-related: among the former, there are chromosomal 17 18 anomalies, genetic syndromes,For and peer infection. Among review maternal conditions, only the most common are: exposition 19 20 to environmental toxins (ex. cigarette smoking), or uteroplacental insufficiency. The mechanism leading to 21 22 FGR involves an abnormal trophoblast invasion of the maternal spiral arteries during pregnancy, which 23 24 results in an incomplete remodelling of these vessels and in the persistence of a high-resistance and low-flow 25 26 uteroplacental circulation, which on its turn determines and insufficient gaseous and nutrient exchange for 27 28 optimal foetal growth [4]. 29 30 31 This results in a cascade of events, including reduced placental perfusion, imbalance in angiogenic factors, 32 33 and in vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), and may lead to 34 35 placenta-mediated complications of pregnancy such as FGR, preeclampsia, placental abruption, and late 36 http://bmjopen.bmj.com/ 37 pregnancy loss [5,6]. 38 39 The management of FGR is based on the prolongation of pregnancy long enough for foetal organs to mature 40 41 while avoiding irreversible foetus’ sufferance [7]. As for pharmacological management, most guidelines 42 43 recommend treatment with low-dose aspirin – in preference by gestational week 16 - for prevention of SGA 44 on September 23, 2021 by guest. Protected copyright. 45 [8–11]. Use of heparin is instead controversial: the Canadian guideline recommends that heparin should be 46 47 offered in selected women [8], although recent evidence indicates that enoxaparin is not effective in 48 49 preventing FGR in women with previous severe or early-onset FGR, or in those with thrombophilia, and can 50 51 52 therefore not be recommended for this purpose [1,12].
Load more

Recommended publications
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • Choice of Drugs in the Treatment of Rheumatoid Arthritis
    RHEUMATOLOGY IN GENERAL PRACTICE 7 Those with predominant but never exclusive involvement of the terminal finger joint, usually associated with changes in the nail of the same finger; they are serologically negative. There may be a swollen finger with loss of the skin markings-a sort of dactylitis, again serologically negative. (2) Those with a much more severe process which produces loss of movement in the spine and changes in the sacroiliac joints much the same as those in ankylosing spondylitis; unlike ankylosing spondylitis, it produces severe deformity often with ankylosis in peripheral joints. Many of the finger joints become deformed and ankylosed. (3) Those cases indistinguishable from rheumatoid arthritis although the majority are sero-negative. The Stevens Johnson syndrome produces acute effusions, particularly in large joints. It is sometimes associated with the rash of erythema multiforme, always with ulceration in the mouth and genital tract; the mouth ulcers are accompanied by sloughing, unlike those of Beh9et's syndrome which we come to next. BehCet's syndrome, originally described as a combination of orogenital ulceration with relapsing iritis, is now expanded to include skin lesions, other eye lesions, lesions of the central nervous system, thrombophlebitis migrans, and arthropathy (occurring in 64 per cent). The onset is acute, often affecting only a single joint and settling without residual trouble. Choice of drugs in the treatment of rheumatoid arthritis Dr Dudley Hart, M.D., F.R.C.P. (Consultant physician, Westminster Hospital and Medical School) There are many potential drugs for the treatment of rheumatoid disease, but what are we treating in this disorder? Pain in rheumatoid arthritis is but one of the symp- toms.
    [Show full text]
  • 18 Analgesics Anti-Inflammatory Drugs and Antipyretics the Dosage of Alfentanil Used Depends on Whether the 2
    18 Analgesics Anti-inflammatory Drugs and Antipyretics The dosage of alfentanil used depends on whether the 2. Virkkilä M, et al. Pharmacokinetics and effects of i.m. alfentanil minutes). However, some considered that there was no over- patient has spontaneous respiration or assisted ventila- as premedication for day-case ophthalmic surgery in elderly pa- all advantage of epidural over intravenous alfentanil either as tients. Br J Anaesth 1993; 71: 507–11. patient-controlled analgesia2 or by continuous infusion.3 tion and on the expected duration of anaesthesia. Doses 3. Hughes DA, Hill DA. Intrathecal alfentanil with and without bupivacaine for analgesia in labour. Anaesthesia 2000; 55: 1. Chrubasik J, et al. Relative analgesic potency of epidural fenta- are adjusted according to the needs of the patient. Chil- 1116–21. nyl, alfentanil, and morphine in treatment of postoperative pain. dren may require higher or more frequent doses than Anesthesiology 1988; 68: 929–33. Administration in children. Alfentanil is licensed in the UK 2. Chauvin M, et al. Equivalence of postoperative analgesia with adults, whereas the elderly or debilitated patients may for use in ventilated children during surgical procedures as an patient-controlled intravenous or epidural alfentanil. Anesth An- require lower or less frequent doses. Obese patients analgesic and adjunct to general anaesthetics or as a primary an- alg 1993; 76: 1251–8. may require doses based on their ideal (lean) body- aesthetic. When used as an adjunct in the maintenance of gen- 3. van den Nieuwenhuyzen MCO, et al. Epidural vs intravenous infusion of alfentanil in the management of postoperative pain weight.
    [Show full text]
  • Bleeding Disorders of Importance in Dental Care and Related Patient Management
    Clinical P RACTIC E Bleeding Disorders of Importance in Dental Care and Related Patient Management Contact Author Anurag Gupta, BDS; Joel B. Epstein, DMD, MSD, FRCD(C); Robert J. Cabay, MD, DDS Dr. Epstein Email: [email protected] ABSTRACT Oral care providers must be aware of the impact of bleeding disorders on the manage- ment of dental patients. Initial recognition of a bleeding disorder, which may indicate the presence of a systemic pathologic process, may occur in dental practice. Furthermore, prophylactic, restorative and surgical dental care of patients with bleeding disorders is best accomplished by practitioners who are knowledgeable about the pathology, com- plications and treatment options associated with these conditions. The purpose of this paper is to review common bleeding disorders and their effects on the delivery of oral health care. For citation purposes, the electronic version MeSH Key Words: blood coagulation/physiology blood coagulation disorders/complications dental care is the definitive version of this article: www.cda-adc.ca/jcda/vol-73/issue-1/77.html entists must be aware of the impact of The patient should be asked for any history bleeding disorders on the management of significant and prolonged bleeding after Dof their patients. Proper dental and med- dental extraction or bleeding from gingivae. ical evaluation of patients is therefore neces- A history of nasal or oral bleeding should sary before treatment, especially if an invasive be noted. Many bleeding disorders, such as dental procedure is planned. Patient evalua- hemophilia and von Willebrand’s disease, tion and history should begin with standard run in families; therefore, a family history medical questionnaires.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • CHAPTER 1 General Introduction
    CHAPTER 1 General Introduction Chapter 1 1.1 General Introduction Drugs are defined as chemical substances that are used to prevent or cure diseases in humans and animals. Drugs can also act as poisons if taken in excess. For example paracetamol overdose causes coma and death. Apart from the curative effect of drugs, most of them have several unwanted biological effects known as side effects. Aspirin which is commonly used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever and as an anti-inflammatory medication, may also cause gastric irritation and bleeding. Also many drugs, such as antibiotics, when over used develop resistance to the patients, microorganisms and virus which are intended to control by drug. Resistance occurs when a drug is no longer effective in controlling a medical condition.1 Thus, new drugs are constantly required to surmount drug resistance, for the improvement in the treatment of existing diseases, the treatment of newly identified disease, minimise the adverse side effects of existing drugs etc. Drugs are classified in number of different ways depending upon their mode of action such as antithrombotic drugs, analgesic, antianxiety, diuretics, antidepressant and antibiotics etc.2 Antithrombotic drugs are one of the most important classes of drugs which can be shortly defined as ―drugs that reduce the formation of blood clots‖. The blood coagulation, also known as haemostasis is a physiological process in which body prevents blood loss by forming stable clot at the site of injury. Clot formation is a coordinated interplay of two fundamental processes, aggregation of platelets and formation of fibrin.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,835,407 B2 Mosher Et Al
    US008835407B2 (12) United States Patent (10) Patent No.: US 8,835,407 B2 Mosher et al. (45) Date of Patent: *Sep. 16, 2014 (54) PHARMACEUTICAL COMPOSITIONS 5,324,718 A 6/1994 Loftsson COMPRISING PRASUGREL AND 5,376,645 A 12, 1994 Stella et al. CYCLODEXTRIN DERVATIVES AND 3:3: A .22 seal. METHODS OF MAKING AND USING THE 5576,328 A 1 1/1996 Herbert et al. SAME 5,632,275 A 5/1997 Browne et al. 5,874,418 A 2f1999 Stella et al. (75) Inventors: Gerold L. Mosher, Kansas City, MO 357. A 1 A.28 t al (US), Stephen G. Michatha, Waltham, 6,071,514. A 6/2000 GrinnellCai Ca. et al. MA (US); Daniel J. Cushing, 6,133,248. A 10/2000 Stella Phoenixville, PA (US) 6,153,746 A 1 1/2000 Shah et al. 6,204.256 B1 3/2001 Shalaby et al. (73) Assignee: CyDex Pharmaceuticals, Inc., La Jolla, 6.248,729 B1 6/2001 Coniglio et al. CA (US) 6,294,192 B1 9/2001 Patel et al. 6,383,471 B1 5, 2002 Chen et al. (*) Notice: Subject to any disclaimer, the term of this 6,451,3396,429,210 B2B1 9/20028, 2002 B styletet alal. patent is extended or adjusted under 35 6,504,030 B1 1/2003 Bousquet et al. U.S.C. 154(b) by 0 days. 6,509.348 B1 1/2003 Ogletree 6,569.463 B2 5/2003 Patel et al. This patent is Subject to a terminal dis- 6,573.381 B1 6/2003 Bousquet et al.
    [Show full text]
  • ( 12 ) United States Patent
    US010272083B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,272 , 083 B2 Hamdy et al. (45 ) Date of Patent: Apr . 30, 2019 (54 ) METHODS OF TREATING CHRONIC ( 56 ) References Cited LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LEUKEMIA USING A BTK U . S . PATENT DOCUMENTS INHIBITOR 7 ,459 ,554 B2 12 /2008 Dong et al . 7 , 825 , 118 B2 11/ 2010 Honigberg et al. (71 ) Applicant: Acerta Pharma B . V ., Oss (NL ) 7 , 960 ,396 B2 6 / 2011 Honigberg et al . 8 , 377 , 946 B1 2 / 2013 Chen et al . 8 ,658 ,794 B2 2 / 2014 deMan et al . (72 ) Inventors : Ahmed Hamdy , Santa Cruz , CA (US ) ; 9 , 290 ,504 B2 3 / 2016 Barf et al . Wayne Rothbaum , New York , NY 2006 / 0084654 A1 4 / 2006 Beck et al . (US ) ; Raquel Izumi, San Carlos , CA 2008 / 0076921 A1 3 / 2008 Honigberg et al. ( US ) ; Brian Lannutti, Solana Beach , 2011/ 0257203 A1 10 / 2011 Honigberg et al . CA (US ) ; Todd Covey , San Carlos , CA 2012 /0053189 Al 3 / 2012 Loury (US ) ; Roger Ulrich , Sammamish , WA 2012 / 0095026 A1 4 /2012 Honigberg et al. (US ) ; Dave Johnson , Aptos, CA (US ) ; 2012/ 0129821 A15 /2012 Honigberg et al . Tjeerd Barf, Ravenstein (NL ) ; Allard 2012 /0135944 A1 5 /2012 Honigberg et al . Kaptein , Zaltbommel (NL ) 2012 /0165328 A1 6 /2012 Honigberg et al . 2013 /0018032 AL 1 /2013 Chen et al . 2013 /0079327 A1 3 / 2013 Yamamoto et al . ( 73 ) Assignee : ACERTA PHARMA B . V . , Oss (NL ) 2013/ 0338172 A1* 12 / 2013 Smyth . .. .. CO7D 487/ 04 514 /262 . 1 ( * ) Notice: Subject to any disclaimer, the term of this 2014 / 0073593 Al 3 / 2014 Conklin et al.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff
    Harmonized Tariff Schedule of the United States (2019) Revision 11 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 11 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T (51) International Patent Classification: (74) Common Representative: UNIVERSITY OF VETER¬ A61K 9/06 (2006.01) A61K 47/32 (2006.01) INARY AND PHARMACEUTICAL SCIENCES A61K 9/14 (2006.01) A61K 47/38 (2006.01) BRNO FACULTY OF PHARMACY; University of A61K 47/10 (2006.01) A61K 9/00 (2006.01) Veterinary and Pharmaceutical Sciences Brno Faculty Of A61K 47/18 (2006.01) Pharmacy, Palackeho 1/3, CZ-61242 Brno (CZ). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CZ20 12/000073 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 2 August 2012 (02.08.2012) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, 201 1-495 11 August 201 1 ( 11.08.201 1) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 2012- 72 1 February 2012 (01.02.2012) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2012-5 11 26 July 2012 (26.07.2012) ZW.
    [Show full text]